FBR analyst Vernon Bernardino was out today with a mix report on shares of Galena Biopharma Inc (NASDAQ:GALE), reiterating an Outperform rating while slashing the price target to $2.00 (from $5.00), which implies an upside of 327% from current levels.
Galena Biopharma, Inc. (GALE) ended last trading session with a change of -3.19 percent. It trades at an average volume of 7.42M shares versus 21.93M shares recorded at the end of last trading session.
What: Investors in the small-cap cancer immunotherapy developer Galena Biopharma (NASDAQ:GALE) are having an awful day. The company's share price has utterly collapsed, falling more than 83% as of 10:00 a.m.
Few companies in any sector have had as tough a couple of weeks as has Galena Biopharma Inc (NASDAQ:GALE). Between February and June, the company gained from $.65 a share to $2.27 a share, on market expectations of positive interim data from its ...
Galena Biopharma Inc (NASDAQ:GALE) shares went up 27.39% or 0.104 points to reach at $0.486 during the course of session. The stock traded in the range of $0.38 - $0.49 during its most recent trading session.